BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

BioNTech will acquire CureVac for approximately $1.25 billion in BioNTech shares, giving CureVac shareholders a 4-6% stake in the combined entity and a 55% premium over the three-month average share price. The acquisition aims to bolster BioNTech's mRNA-based cancer immunotherapy research and development, leveraging its COVID-19 vaccine success with Pfizer, while also resolving ongoing patent disputes between the two companies; CureVac shares surged 27% on the news, while BioNTech shares declined 2%.

Analysis

BioNTech has announced the acquisition of its German peer CureVac for approximately $1.25 billion in BioNTech shares, a deal offering CureVac shareholders a substantial 55% premium over the three-month average share price and resulting in a 4%-6% stake in the enlarged BioNTech. This strategic move is designed to significantly enhance BioNTech's research and development capabilities in mRNA-based cancer immunotherapies, leveraging the considerable financial resources accumulated from its successful COVID-19 vaccine partnership with Pfizer. The acquisition also pragmatically resolves ongoing patent infringement litigation initiated by CureVac against BioNTech. Following the announcement, CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at 1.04 billion euros, while BioNTech's shares declined by 2%, a typical market reaction for an acquirer. This transaction follows BioNTech's recent high-profile agreement with Bristol Myers Squibb for up to $11.1 billion to co-develop a next-generation cancer immunotherapy, further cementing its strategic focus on oncology post-pandemic. CureVac itself had pivoted to oncology about a year ago after its COVID-19 vaccine development proved unsuccessful and it sold its influenza and COVID-19 vaccine development to GSK. The deal, which includes a collar mechanism based on BioNTech's American Depositary Share price fluctuations, has garnered support from CureVac's major shareholder Dietmar Hopp (37% stake) and a welcoming preliminary response from the German government (holder of a 13% stake in CureVac), which views the combination favorably as the creation of a "new German biotech champion."

Key Decisions for Investors

• BioNTech investors should consider the acquisition's long-term strategic value in bolstering its oncology pipeline and resolving patent disputes, despite potential near-term share dilution and the need to monitor integration success.
• CureVac shareholders are presented with a significant premium and an exchange into shares of a financially stronger company with a broader R&D focus; they should assess the exchange terms, including the collar mechanism, and BioNTech's future prospects.
• Investors should recognize this deal as indicative of ongoing consolidation and strategic repositioning within the biotech sector, particularly for companies with mRNA expertise shifting towards high-value oncology markets, and may look for further M&A opportunities.